Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects

This paper, co-authored by European psychedelic researchers as well as European Medicines Agency representatives was recently published. It outlines key knowledge gaps “that may be imperative for a successful implementation of psychedelic drugs as medicines”. It provides a summary of topics discussed at the European College of Neuropsychopharmacology at the New Frontiers Meeting in Nice and paves the way for the upcoming EMA workshop on psychedelics.

Previous
Previous

PAREA EU Insights February 2024

Next
Next

Psychedelic-Assisted Therapy for PTSD: On the Verge of FDA Approval